The AgRP and GH/IGF-1 Axis in Children
ConditionGrowth Hormone Deficiency
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age5-17
SponsorColumbia University
About this trial
Recent data support the existence of a GH-Agouti-related peptide (AgRP) axis. The neuropeptide AgRP promotes food intake and has important effects on energy homeostasis. Recent evidence suggest that GH stimulates AgRP and AgRP may mediate some of GH's important nutritional and metabolic effects. main goals of this project are to characterize, for the first time, plasma levels of AgRP in children and to determine how these relate to GH and IGF-1 levels, age, body composition, clinical and other endocrine parameters. To accomplish this, we will conduct two studies, one being a cross-sectional study that will measure AgRP levels in 140 healthy children ages 5-17 and the second being a prospective study that will measure the change in plasma AgRP levels in response to GH treatment in 16 children who receive this as part of their clinical care for GH deficiency or short stature.
Eligibility criteria
Qualifiers
Ambulatory male and female children aged 5-17 years
Normal weight at birth
Height between the 3rd and 99th percentiles of the mean as per the CDC growth percentiles.
Disqualifiers
Genetic defects, chronic illnesses.
Current prescription medication use
Use of glucocorticoids, thyroid hormone or medications that may affect the GH-IGF-1 axis within 6 months of study entry.
Ambulatory male and female children aged 5-9 years who are prepubertal
Trial design
Treatments tested in this trial
- Not listed
Trial groups
156 Participants
are grouped into 3 trial groupsLocations
Sponsors and collaborators
Source ClinicalTrials.gov